IL15 and Ewing sarcoma: Irrespective of the exact mechanism, however, the observation that chemotherapy-resistant Ewing sarcoma do not exhibit cross-resistance to IL-15-activated natural killer cell-mediated immunotherapy suggests that cytokine-activated natural killer cell therapies may represent promising immunotherapeutic options for patients with Ewing sarcoma.